

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF
FIRST PATIENT ENROLLMENT FOR
DTCP-HIB-MCV4 COMBINED VACCINE

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Phase I clinical trial for the absorbed diphtheria, tetanus and acellular pertussis (components) (the “**DTcP**”) Haemophilus Influenzae Type b (Conjugate) (the “**Hib**”) – Group ACYW135 Meningococcal (Conjugate) (the “**MCV4**”) combined vaccine (the “**DTcP-Hib-MCV4 Combined Vaccine**”) developed by the Company was officially initiated recently and the first trial patient case has been formally enrolled.

To leverage the Company’s product pipeline layout and meet the market demand for combined vaccines, the Company intends to develop the DTcP-Hib-MCV4 Combined Vaccine to achieve a differentiated competitive stance. The Phase I clinical trial is designed to assess the safety and immunogenicity of the DTcP-Hib-MCV4 Combined Vaccine in subjects aged between 2 months to 6 years.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 19, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.